|
1
|
Duan J, Wang Y, Chen Y, Wang Y, Li Q, Liu J, Fu C, Cao C, Cong Z, Su M. Silencing LY6D Expression Inhibits Colon Cancer in Xenograft Mice and Regulates Colon Cancer Stem Cells' Proliferation, Stemness, Invasion, and Apoptosis via the MAPK Pathway. Molecules 2023; 28:7776. [PMID: 38067506 PMCID: PMC10708431 DOI: 10.3390/molecules28237776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2023] [Revised: 11/19/2023] [Accepted: 11/23/2023] [Indexed: 12/18/2023] Open
Abstract
This study explored the role of lymphocyte antigen 6 family member D (LY6D) in colon cancer stem cells' (CCSCs) proliferation and invasion. LY6D was knocked down using siRNA, and the down-regulation of LY6D was verified using Western blotting. After LY6D knockdown, CCSCs' proliferation, stemness, and invasion were suppressed, whereas apoptosis was increased. Gene Ontology (GO) enrichment analysis revealed that the differentially expressed genes (DEGs) between siLY6D and the negative control groups were significantly enriched in the cell-substrate adherens junction, focal adhesion, and cell-substrate junction terms. Meanwhile, the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that the DEGs were significantly enriched in the MAPK pathway. In addition, Western blotting results showed that pBRAF and pERK1/2, cascade kinases of the MAPK pathway, were significantly down-regulated after LY6D knockdown. In addition, nude mice xenograft experiments showed that the siLY6D treatment decreased tumor sizes and weights and improved tumor-bearing mice survival rates compared with the control group. In conclusion, these findings indicate that LY6D, which is highly expressed in CCSCs, is a key factor involved in tumor growth and development and might be a potential cancer marker and therapeutic target for colon cancer.
Collapse
Affiliation(s)
- Jinyue Duan
- Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China; (J.D.); (Y.C.); (Y.W.); (Q.L.); (J.L.); (C.C.)
| | - Yi Wang
- Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China; (J.D.); (Y.C.); (Y.W.); (Q.L.); (J.L.); (C.C.)
| | - Yuanyuan Chen
- Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China; (J.D.); (Y.C.); (Y.W.); (Q.L.); (J.L.); (C.C.)
| | - Yujue Wang
- Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China; (J.D.); (Y.C.); (Y.W.); (Q.L.); (J.L.); (C.C.)
| | - Qisen Li
- Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China; (J.D.); (Y.C.); (Y.W.); (Q.L.); (J.L.); (C.C.)
| | - Jinrui Liu
- Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China; (J.D.); (Y.C.); (Y.W.); (Q.L.); (J.L.); (C.C.)
| | - Changhao Fu
- VA Palo Alto Health Care System, Medical School, Stanford University, Palo Alto, CA 94304, USA;
| | - Chenyu Cao
- Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China; (J.D.); (Y.C.); (Y.W.); (Q.L.); (J.L.); (C.C.)
| | - Zhongyi Cong
- Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China; (J.D.); (Y.C.); (Y.W.); (Q.L.); (J.L.); (C.C.)
| | - Manman Su
- Department of Regenerative Medicine, School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China; (J.D.); (Y.C.); (Y.W.); (Q.L.); (J.L.); (C.C.)
| |
Collapse
|